RxDoctor Payments Data

Milind Parikh, MD

Cardiovascular Disease · Orlando, FLNPI 1467619775

Payments from drug & device makers

$7,800in general payments, 2019–2025

Across 113 payments — averaging $69.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abbott$2K
  • Biotronik Inc.$1K
  • Atricure, Inc.$691
  • Cleerly, Inc.$392
  • Baylis Medical Company Inc$238
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$95012%
  • Travel & lodging$2,97538%
  • Food & beverage$3,65447%
  • Education$2213%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,800 in reported general payments places this provider in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,140,327
Medicare patients
1,188
Services billed
9,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban650$747,832
XareltoRivaroxaban188$225,357
EntrestoSacubitril/Valsartan92$140,121
MultaqDronedarone Hcl50$74,466
JardianceEmpagliflozin71$71,763
FarxigaDapagliflozin Propanediol33$50,401
Repatha SureclickEvolocumab36$44,582
Praluent PenAlirocumab33$27,142
VascepaIcosapent Ethyl25$16,014
Metoprolol Succinate621$9,462
LivaloPitavastatin Calcium13$8,011
Rosuvastatin Calcium491$7,653
Flecainide Acetate131$6,272
Ranolazine ErRanolazine52$5,245
Ezetimibe155$5,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$747,832650 claims
Johnson & JohnsonXarelto$62$225,357188 claims
NovartisEntresto$63$140,12192 claims
Sanofi-aventis U.S. LLCMultaq$33$74,46650 claims
Boehringer IngelheimJardiance$130$71,76371 claims
AstraZenecaFarxiga$14$50,40133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →